Twice-Yearly Dosing of Inclisiran Provides Significant LDL-C Lowering
Twice-yearly dosing with inclisiran sodium resulted in significant lowering of low-density lipoprotein cholesterol.
Twice-yearly dosing with inclisiran sodium resulted in significant lowering of low-density lipoprotein cholesterol.
Treatment with sacubitril/valsartan provides greater benefits in certain patients with HFpEF, according to analyses from the phase 3 PARAGON-HF trial.
Treatment with empagliflozin, a SGLT2 inhibitor, was associated with reduced risk of hospitalization for heart failure.
Opioid overdose victims who suffer cardiac arrest are distinctly different from other cardiac arrest patients, yet they may be more likely than others to survive long enough to be admitted to a hospital.
Similar to results among people who smoked traditional cigarettes, e-cigarette smoking negatively effects heart disease risk factors, namely, cholesterol, triglycerides and glucose levels, and decreases blood flow in the heart.
Higher rates of depression, anxiety, and attention-deficit/hyperactivity disorder have been linked to congenital heart disease; however, data thus far have been limited for younger patients with cardiac arrhythmia.
The presence of key cardiovascular disease risk factors may be associated with an increased risk of developing cancer.
Tight, intensive blood pressure control was found to improve residual survival length in middle aged and older individuals at risk for cardiovascular disease.
Obese people who undergo weight-reduction surgery live longer than obese people who do not have surgery.
About one in three individuals with ASCVD did not receive an influenza vaccination in the past year.
Please login or register first to view this content.